FIRST Fund – River BioMedics Raises Seed Investment to Progress its Cardiovascular Disease Programs
Eur 1.8 million seed funding to progress its pipeline of cardiovascular disease targetsCompany appoints Nicky Cooper as its Chief Executive OfficerFinancing round co-led by FIRST Fund, KIKK Capital and Oost NL Enschede, The Netherlands, 20 January 2022 - River...
Lonza, Forbion, and BioGeneration Ventures Extend Collaboration to Add Development and Manufacturing Services of Small Molecules
Joint Venture Partners Forbion and BioGeneration Ventures extend collaboration with Lonza to include services relating to small molecules for the portfolio companies of both entitiesThe collaboration continues to provide early de-risking, development and...
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
Amsterdam, The Netherlands, 17 December 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD...
Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s...
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
Leiden, The Netherlands, 15 December 2021 - VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the first subjects in its first-in-human study for lead compound...
Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing dealMersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology...
Confo Therapeutics Enters Collaborative Agreement with Regeneron
Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron...
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor...
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity
Naarden, The Netherlands, 16 November 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b...
BGV portfolio company Dunad Ltd announces $1.3B strategic collaboration with Novartis on protein degrader therapies
Amsterdam, The Netherlands, 02 November 2021 - BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma today announces that Dunad Therapeutics (“Dunad”), a biopharmaceutical company focusing on the development of protein degradation therapies,...